Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

Birtle, Alison; Johnson, Mark; Chester, John; J. Jones, Robert; Dolling, David; T. Bryan, Richard; Harris, Christopher; Winterbottom, Andrew; Blacker, Anthony; W.F. Catto, James; Chakraborti, Prabir; Donovan, Jenny; Anthony Elliott, Paul; French, Ann; Jagdev, Satinder; Jenkins, Benjamin; X. Keeley, Francis; Kockelbergh, Roger; Powles, Thomas; Wagstaff, John; Wilson, Caroline; Todd, Rachel; Lewis, Rebecca; Hall, Emma

doi:10.1016/s0140-6736(20)30415-3

Public

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

Published in The Lancet • Mar 5, 2020

Authors:

Alison Birtle

Mark Johnson

John Chester

Abstract

Background Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary bladder. No international consensus exists on the benefit of adjuvant chemotherapy for patients with UTUCs after nephroureterectomy with curat...

Subject

Medicine

Open label

Adjuvant

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!